TY - CHAP AU - Stock, W. PY - 2006 DA - 2006// TI - Controversies in Treatment of AML: Case-based Discussion BT - Hematology Am Soc Hematol Educ Program ID - Stock2006 ER - TY - JOUR AU - Marie, J. P. AU - Legrand, O. PY - 1999 DA - 1999// TI - MDR1/P-GP expression as a prognostic factor in acute leukemias JO - Adv Exp Med Biol VL - 457 UR - https://doi.org/10.1007/978-1-4615-4811-9_1 DO - 10.1007/978-1-4615-4811-9_1 ID - Marie1999 ER - TY - JOUR AU - Leith, C. P. AU - Kopecky, K. J. AU - Godwin, J. AU - McConnell, T. AU - Slovak, M. L. AU - Chen, I. M. AU - Head, D. R. AU - Appelbaum, F. R. AU - Willman, C. L. PY - 1997 DA - 1997// TI - Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study JO - Blood VL - 89 ID - Leith1997 ER - TY - JOUR AU - Legrand, O. AU - Perrot, J. Y. AU - Simonin, G. AU - Baudard, M. AU - Marie, J. P. PY - 2001 DA - 2001// TI - JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia JO - Blood VL - 97 UR - https://doi.org/10.1182/blood.V97.2.502 DO - 10.1182/blood.V97.2.502 ID - Legrand2001 ER - TY - CHAP AU - Tallman, M. S. PY - 2005 DA - 2005// TI - New strategies for the treatment of acute myeloid leukaemia including antibodies and other novel agents BT - American Society Hematology ID - Tallman2005 ER - TY - JOUR AU - List, A. F. AU - Kopecky, K. J. AU - Willman, C. L. AU - Head, D. R. AU - Persons, D. L. AU - Slovak, M. L. AU - Dorr, R. AU - Karanes, C. AU - Hynes, H. E. AU - Doroshow, J. H. AU - Shurafa, M. AU - Appelbaum, F. R. PY - 2001 DA - 2001// TI - Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study JO - Blood VL - 98 UR - https://doi.org/10.1182/blood.V98.12.3212 DO - 10.1182/blood.V98.12.3212 ID - List2001 ER - TY - JOUR AU - Linksvan der Holt, B. AU - Löwenberg, B. AU - Burnett, A. K. AU - Knauf, W. U. AU - Shepherd, J. AU - Piccaluga, P. P. AU - Ossenkoppele, G. J. AU - Verhoef, G. E. AU - Ferrant, A. AU - Crump, M. AU - Selleslag, D. AU - Theobald, M. AU - Fey, M. F. AU - Vellenga, E. AU - Dugan, M. AU - Sonneveld, P. PY - 2005 DA - 2005// TI - The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-04-1395 DO - 10.1182/blood-2005-04-1395 ID - Linksvan der Holt2005 ER - TY - JOUR AU - Wacher, V. J. AU - Wu, C. Y. AU - Benet, L. Z. PY - 1995 DA - 1995// TI - Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy JO - Mol Carcinog VL - 13 UR - https://doi.org/10.1002/mc.2940130302 DO - 10.1002/mc.2940130302 ID - Wacher1995 ER - TY - JOUR AU - Fischer, V. AU - Rodríguez-Gascón, A. AU - Heitz, F. AU - Tynes, R. AU - Hauck, C. AU - Cohen, D. AU - Vickers, A. E. PY - 1998 DA - 1998// TI - The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite JO - Drug Metab Dispos VL - 26 ID - Fischer1998 ER - TY - JOUR AU - Sonneveld, P. AU - Burnett, A. AU - Vossebeld, P. AU - Ben-Am, M. AU - Rosenkranz, G. AU - Pfister, C. AU - Verhoef, G. AU - Dekker, A. AU - Ossenkoppele, G. AU - Ferrant, C. AU - Yin, L. AU - Gratwohl, A. AU - Kovacsovics, T. AU - Vellenga, E. AU - Capdeville, R. AU - Löwenberg, B. PY - 2000 DA - 2000// TI - Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia JO - Hematol J VL - 1 UR - https://doi.org/10.1038/sj.thj.6200050 DO - 10.1038/sj.thj.6200050 ID - Sonneveld2000 ER - TY - JOUR AU - Kolitz, J. E. AU - George, S. L. AU - Dodge, R. K. AU - Hurd, D. D. AU - Powell, B. L. AU - Allen, S. L. AU - Velez-Garcia, E. AU - Moore, J. O. AU - Shea, T. C. AU - Hoke, E. AU - Caligiuri, M. A. AU - Vardiman, J. W. AU - Bloomfield, C. D. AU - Larson, R. A. PY - 2004 DA - 2004// TI - Cancer and Leukemia Group B. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621 JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.11.106 DO - 10.1200/JCO.2004.11.106 ID - Kolitz2004 ER - TY - JOUR AU - Shepard, R. L. AU - Cao, J. AU - Starling, J. J. AU - Dantzig, A. H. PY - 2003 DA - 2003// TI - Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979 JO - Int J Cancer VL - 103 UR - https://doi.org/10.1002/ijc.10792 DO - 10.1002/ijc.10792 ID - Shepard2003 ER - TY - JOUR AU - Dantzig, A. H. AU - Shepard, R. L. AU - Law, K. L. AU - Tabas, L. AU - Pratt, S. AU - Gillespie, J. S. AU - Binkley, S. N. AU - Kuhfeld, M. T. AU - Starling, J. J. AU - Wrighton, S. A. PY - 1999 DA - 1999// TI - Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities JO - J Pharmacol Exp Ther VL - 290 ID - Dantzig1999 ER - TY - JOUR AU - Related, A. r. t. i. c. l. e. s. AU - LinksSandler, A. AU - Gordon, M. AU - De Alwis, D. P. AU - Pouliquen, I. AU - Green, L. AU - Marder, P. AU - Chaudhary, A. AU - Fife, K. AU - Battiato, L. AU - Sweeney, C. AU - Jordan, C. AU - Burgess, M. AU - Slapak, C. A. PY - 2004 DA - 2004// TI - A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-03-0644 DO - 10.1158/1078-0432.CCR-03-0644 ID - Related2004 ER - TY - JOUR AU - Gerrard, G. AU - Payne, E. AU - Baker, R. J. AU - Jones, D. T. AU - Potter, M. AU - Prentice, H. G. AU - Ethell, M. AU - McCullough, H. AU - Burgess, M. AU - Mehta, A. B. AU - Ganeshaguru, K. PY - 2004 DA - 2004// TI - Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine JO - Haematologica VL - 89 ID - Gerrard2004 ER - TY - JOUR AU - Linenberger, M. L. AU - Hong, T. AU - Flowers, D. AU - Sievers, E. L. AU - Gooley, T. A. AU - Bennett, J. M. AU - Berger, M. S. AU - Leopold, L. H. AU - Appelbaum, F. R. AU - Bernstein, I. D. PY - 2001 DA - 2001// TI - Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin JO - Blood VL - 98 UR - https://doi.org/10.1182/blood.V98.4.988 DO - 10.1182/blood.V98.4.988 ID - Linenberger2001 ER - TY - JOUR AU - Walter, R. B. AU - Raden, B. W. AU - Hong, T. C. AU - Flowers, D. A. AU - Bernstein, I. D. AU - Linenberger, M. L. PY - 2003 DA - 2003// TI - Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells JO - Blood VL - 102 UR - https://doi.org/10.1182/blood-2003-02-0396 DO - 10.1182/blood-2003-02-0396 ID - Walter2003 ER - TY - JOUR AU - Zhou, D. C. AU - Ramond, S. AU - Viguié, F. AU - Faussat, A. M. AU - Zittoun, R. AU - Marie, J. -. P. PY - 1996 DA - 1996// TI - Progressive resistance to homoharringtonine in human myeloleukemia K562 cells: relationship to sequential emergence of MRP and MDR1 gene overexpression and MDR1 gene translation JO - Int J Cancer VL - 65 UR - https://doi.org/3.0.CO;2-9 DO - 3.0.CO;2-9 ID - Zhou1996 ER - TY - JOUR AU - Yanase, K. AU - Tsukahara, S. AU - Asada, S. AU - Ishikawa, E. AU - Imai, Y. AU - Sugimoto, Y. PY - 2004 DA - 2004// TI - Gefitinib reverses breast cancer resistance protein-mediated drug resistance JO - Mol Cancer Ther VL - 3 ID - Yanase2004 ER - TY - JOUR AU - Sarkadi, B. AU - Ozvegy-Laczka, C. AU - Nemet, K. AU - Varadi, A. PY - 2004 DA - 2004// TI - ABCG2 – a transporter for all seasons JO - FEBS Lett VL - 567 UR - https://doi.org/10.1016/j.febslet.2004.03.123 DO - 10.1016/j.febslet.2004.03.123 ID - Sarkadi2004 ER - TY - JOUR AU - Shepard, R. L. AU - Cao, J. AU - Starling, J. J. AU - Dantzig, A. H. PY - 2003 DA - 2003// TI - Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979 JO - Int J Cancer VL - 103 UR - https://doi.org/10.1002/ijc.10792 DO - 10.1002/ijc.10792 ID - Shepard2003 ER - TY - JOUR AU - Benderra, Z. AU - Faussat, A. M. AU - Sayada, L. AU - Perrot, J. Y. AU - Tang, R. AU - Chaoui, D. AU - Morjani, H. AU - Marzac, C. AU - Marie, J. P. AU - Legrand, O. PY - 2005 DA - 2005// TI - MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-1895 DO - 10.1158/1078-0432.CCR-04-1895 ID - Benderra2005 ER - TY - JOUR AU - Benderra, Z. AU - Faussat, A. M. AU - Sayada, L. AU - Perrot, J. Y. AU - Chaoui, D. AU - Marie, J. P. AU - Legrand, O. PY - 2004 DA - 2004// TI - Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-0795 DO - 10.1158/1078-0432.CCR-04-0795 ID - Benderra2004 ER - TY - JOUR AU - Morschhauser, F. AU - Zinzani, P. L. AU - Burgess, M. AU - Sloots, L. AU - Bouafia, F. AU - Dumontet, C. PY - 2007 DA - 2007// TI - Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma JO - Leuk Lymphoma VL - 48 UR - https://doi.org/10.1080/10428190701190169 DO - 10.1080/10428190701190169 ID - Morschhauser2007 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/51/prepub UR - http://www.biomedcentral.com/1471-2407/8/51/prepub ID - ref25 ER -